register

News - Pharmaceuticals

Patient advocacy leaders and researchers clash over $96 million pharma funding

Health Industry Hub | October 20, 2026 |

New research quantifies $96 million in pharmaceutical funding to Australian patient organisations, raising questions about industry influence on health advocacy. Yet, patient advocacy leaders defend these partnerships as essential, insisting existing safeguards protect their independence.

The University of Sydney research found that 390 Australian patient groups received pharmaceutical funding over the 10-year study period, with almost half (47.9%) of all disclosed payments concentrated disproportionately among 13 organisations.

Macular Disease Foundation Australia topped the list of funding beneficiaries, securing $6.57 million, followed by Rare Cancers Australia with $6.05 million and Lung Foundation Australia with $4.82 million. Cancer-related organisations collectively attracted more than $24 million, accounting for approximately one-quarter of all funding identified in the study.

“Patient groups require funding to continue operating, much of which currently comes from the pharmaceutical industry. This can put pressure on these groups to align with the interests of their funders in order to secure future funding, impairing the ability of patient groups to be an unbiased voice for their communities,” said lead author Dr Ashleigh Hooimeyer from Sydney Pharmacy School in the Faculty of Medicine and Health and the Charles Perkins Centre.

“Australia’s largely self-regulated disclosure system which only applies to a part of the pharmaceutical sector may not adequately address potential conflicts of interest or ensure public confidence in the independence of consumer advocacy,” she added.

Patient groups defend industry partnerships

Patient advocacy leaders defended pharmaceutical funding as essential to sustaining services, rejecting suggestions that industry support compromises their independence.

Deidre Mackechnie, CEO of the Australian Patient Advocacy Alliance (APAA), argued that an organisation’s mission remains the defining influence on its advocacy, regardless of its funding sources.

“Patient advocacy organisations are established with a vision for their specific patient cohort. It is that vision that remains our ‘north star’ regardless of where our funding comes from,” Mackechnie told Health Industry Hub.

Funding diversification and a clear separation between financial arrangements and advocacy decisions are critical to protecting organisational independence, particularly as not-for-profits contend with persistent funding shortfalls.

“Shortfalls in government funding, sometimes no funding, plus a decline in available donor funds absolutely contributes to the need to get funding from a range of sources to continue our work,” Mackechnie emphasised.

However, she rejected the idea that government funding should become the sole alternative to industry support, arguing that dependence on any single source could create its own conflicts of interest.

Top recipients reject suggestions of compromised independence

The largest funding recipients cited in the study defended their arrangements, stressing that industry contributions do not determine their organisational priorities.

Dr Kathy Chapman, CEO of Macular Disease Foundation Australia (MDFA), said the organisation’s decisions remained independent despite receiving support from multiple sources.

“MDFA’s organisational priorities and positions are determined independently – with strong governance, transparent disclosure, and clear agreements to protect that independence. While we receive funding from a range of sources, including industry, our priorities are determined solely by the needs of the macular disease community,” stressed Dr Chapman. “Limited and often short-term government funding means patient groups need a diverse mix of income to sustain essential services.”

She acknowledged the importance of disclosure but argued that “it must be supported by strong governance. We support practical, sector-wide safeguards developed with patient organisations and communities”.

Christine Cockburn, CEO of Rare Cancers Australia, similarly defended industry funding as one component of a broader partnership model.

“To achieve equitable outcomes for people with rare cancers, we work with a diverse range of partners and supporters to raise awareness, increase investment and address system gaps,” Cockburn told Health Industry Hub. “Industry supporters do not have editorial or directional input on project delivery, and their support is openly declared.”

She argued that sustained investment across the healthcare system was necessary to improve patient outcomes, with patient organisations, clinicians, researchers, governments and industry all contributing to that effort.

“We are very proud of our diverse and sustainable funding model. Disclosure is important for funding from any source, including government, industry and community. Patient organisations publish detailed financial reports and manage the risks of all funding sources,” Cockburn added.

Lung Foundation Australia justified the organisation’s policies governing corporate partnerships.

“The total investment in Lung Foundation Australia represents approximately 5% of gross revenue over the last 10 years,” explained Mark Brooke, CEO of Lung Foundation Australia. “We are funded by a range of philanthropic, government, private donor, community, and industry funding. By working with government, industry, and the community we have together achieved significant health reform including the National Lung Cancer Screening program.”

The organisation noted that it “can only reflect on its processes” but was “very confident” that its “risk strategy, policy, and processes are both transparent and best practice”.

Medicines Australia says disclosure alone cannot settle the scrutiny

Senior research author Barbara Mintzes, Professor of Evidence-Based Pharmaceutical Policy at the Charles Perkins Centre and School of Pharmacy, said stronger safeguards were needed to protect the credibility of patient advocacy.

“We’re calling for greater transparency and oversight of relationships between pharmaceutical companies and patient organisations to help safeguard trust in Australia’s health advocacy sector,” stated Professor Mintzes.

Medicines Australia, the peak body for the research-based pharmaceutical industry, reaffirmed the legitimacy of collaboration with patient organisations while acknowledging companies’ responsibility to prevent inappropriate influence.

“The Medicines Australia Code of Conduct and Working Together Guide recognise the value of collaboration between industry and patient organisations, while requiring companies to consider, on a case-by-case basis, whether any proposed support or collaboration is capable of withstanding professional and public scrutiny,” stated Liz de Somer, CEO of Medicines Australia.

On the question of whether industry support crosses the line into influencing public debate, de Somer rejected the premise that advocacy and public influence were inherently incompatible.

“The line is not between supporting patients and influencing public debate; it is between appropriate and inappropriate influence,” she insisted. “Disclosure is only one part of a broader framework designed to minimise the risk of inappropriate influence.”

De Somer challenged the extent to which the study’s findings could support conclusions about the adequacy of current safeguards.

“While the research analyses funding flows, it does not examine whether funding has influenced the activities or positions of patient organisations, making it difficult to assess whether additional reporting alone would address the concerns raised,” she emphasised.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.


News - MedTech & Diagnostics

Roche unlocks new horizons for genomic research in Asia Pacific

Roche unlocks new horizons for genomic research in Asia Pacific

Health Industry Hub | November 9, 2026 |

Roche is advancing its next-generation sequencing (NGS) ambitions in Asia Pacific following the global launch of AXELIOS 1 in June […]

More


News - Pharmaceuticals

'Unexpected and Surprising': Novartis’ Lp(a) setback raises tough questions for Amgen and Lilly - Professor Stephen Nicholls, Victorian Heart Hospital

‘Unexpected and surprising’: Novartis Lp(a) setback raises tough questions for Amgen and Lilly

Health Industry Hub | November 9, 2026 |

The failure of Novartis’ lipoprotein(a) [Lp(a)] therapy to translate substantial biomarker reductions into meaningful cardiovascular benefits has been met with […]

More


News - MedTech & Diagnostics

More public hospitals turn to same-day hip and knee surgery but recovery risks persist

More public hospitals turn to same-day hip and knee surgery, but key blind spots persist

Health Industry Hub | November 9, 2026 |

Same-day hip and knee replacements to ease surgical waiting lists are being trialled at The Royal Adelaide Hospital (RAH), but […]

More


News - Pharmaceuticals

TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning

TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning

Health Industry Hub | November 9, 2026 |

The Therapeutic Goods Administration (TGA) approval of Novo Nordisk’s oral GLP-1 receptor agonist Wegovy (semaglutide) is introducing a new dimension to […]

More


This content is copyright protected. Please subscribe to gain access.